Patents by Inventor Naomi S. RAJAPAKSA
Naomi S. RAJAPAKSA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12247032Abstract: Compounds of formula (I) wherein R1, R2, R3, R4, R5 and R6 are as defined herein, and salts thereof, that are useful as JAK kinase inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.Type: GrantFiled: December 8, 2022Date of Patent: March 11, 2025Assignee: Genentech, Inc.Inventors: Mark Edward Zak, Naomi S. Rajapaksa, Yun-Xing Cheng, Jessica Grandner, Daniel G. M. Shore, F. Anthony Romero, Marian C. Bryan
-
Publication number: 20230167123Abstract: Compounds of formula (I) wherein R1, R2, R3, R4, R5 and R6 are as defined herein, and salts thereof, that are useful as JAK kinase inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.Type: ApplicationFiled: December 8, 2022Publication date: June 1, 2023Applicant: Genentech, Inc.Inventors: Mark Edward Zak, Naomi S. Rajapaksa, Yun-Xing Cheng, Jessica Grandner, Daniel G.M. Shore, F. Anthony Romero, Marian C. Bryan
-
Publication number: 20230016791Abstract: wherein R1, R2, R3, R4, R5 and R6 are as defined herein, and salts thereof that are useful as JAK kinse inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.Type: ApplicationFiled: August 24, 2022Publication date: January 19, 2023Applicant: Genentech, Inc.Inventors: Mark Edward Zak, Naomi S. Rajapaksa, Yun-Xing Cheng, Jessica Marie Grandner, Daniel G.M. Shore, Marian C. Bryan
-
Patent number: 11453671Abstract: Compounds of formula (I) wherein R1, R2, R3, R4, R5 and R6 are as defined herein, and salts thereof that are useful as JAK kinse inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.Type: GrantFiled: June 16, 2020Date of Patent: September 27, 2022Assignee: Genentech, Inc.Inventors: Mark Edward Zak, Naomi S. Rajapaksa, Yun-Xing Cheng, Jessica Grandner, Daniel G. M. Shore, Marian C. Bryan
-
Patent number: 11434250Abstract: Compounds of Formula I and methods of use as Interleukin-1 Receptor Associated Kinase 4 (IRAK4) inhibitors are described herein.Type: GrantFiled: April 30, 2020Date of Patent: September 6, 2022Assignee: Genentech, Inc.Inventors: Marian C. Bryan, Joy Drobnick, James Richard Kiefer, Jr., Aleksandr Kolesnikov, Naomi S. Rajapaksa
-
Publication number: 20220106322Abstract: Compounds and salts thereof that are useful as JAK kinase inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.Type: ApplicationFiled: December 16, 2021Publication date: April 7, 2022Applicant: Genentech, Inc.Inventors: Mark Edward Zak, Naomi S. Rajapaksa, Yun-Xing Cheng, Wei Li, Daniel G.M. Shore, F. Anthony Romero, Marian C. Bryan
-
Patent number: 11034698Abstract: Compounds of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, and methods of use as Interleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.Type: GrantFiled: December 16, 2019Date of Patent: June 15, 2021Assignee: Genentech, Inc.Inventors: Marian C. Bryan, Steven Do, Joy Drobnick, Alberto Gobbi, Tamiko Katsumoto, James Richard Kiefer, Jr., Jun Liang, Naomi S. Rajapaksa, Yongsheng Chen, Liqiang Fu, Kwong Wah Lai, Zhiguo Liu, John Wai, Fei Wang
-
Patent number: 10899774Abstract: Compounds of Formula 0, and stereoisomers and pharmaceutically acceptable salts thereof, as well as methods of use as Interleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.Type: GrantFiled: December 16, 2019Date of Patent: January 26, 2021Assignee: Genentech, Inc.Inventors: Marian C. Bryan, Joy Drobnick, Alberto Gobbi, Tamiko Katsumoto, Naomi S. Rajapaksa, James Richard Kiefer, Jr.
-
Patent number: 10899772Abstract: Compounds of Formula 0, and stereoisomers and pharmaceutically acceptable salts thereof, as well as methods of use as Interleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.Type: GrantFiled: December 16, 2019Date of Patent: January 26, 2021Assignee: Genentech, Inc.Inventors: Marian C. Bryan, Steven Do, Tamiko Katsumoto, Jun Liang, Naomi S. Rajapaksa, James Richard Kiefer, Jr., Liqiang Fu
-
Publication number: 20200399275Abstract: Compounds of formula (I) wherein R1, R2, R3, R4, R5 and R6 are as defined herein, and salts thereof that are useful as JAK kinse inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.Type: ApplicationFiled: June 16, 2020Publication date: December 24, 2020Applicant: Genentech, Inc.Inventors: Mark Edward Zak, Naomi S. Rajapaksa, Yun-Xing Cheng, Jessica Grandner, Daniel G.M. Shore, Marian C. Bryan
-
Publication number: 20200399274Abstract: Compounds of formula (I) wherein R1, R2, R3, R4, R5 and R6 are as defined herein, and salts thereof, that are useful as JAK kinase inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.Type: ApplicationFiled: June 16, 2020Publication date: December 24, 2020Applicant: Genentech, Inc.Inventors: Mark Edward Zak, Naomi S. Rajapaksa, Yun-Xing Cheng, Jessica Grandner, Daniel G.M. Shore, F. Anthony Romero, Marian C. Bryan
-
Publication number: 20200262845Abstract: Compounds of Formula I and methods of use as Interleukin-1 Receptor Associated Kinase 4 (IRAK4) inhibitors are described herein.Type: ApplicationFiled: April 30, 2020Publication date: August 20, 2020Applicant: Genentech, Inc.Inventors: Marian C. BRYAN, Joy DROBNICK, James Richard KIEFER, JR., Aleksandr KOLESNIKOV, Naomi S. RAJAPAKSA
-
Publication number: 20200123166Abstract: Compounds of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, and methods of use as Interleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.Type: ApplicationFiled: December 16, 2019Publication date: April 23, 2020Applicant: Genentech, Inc.Inventors: Marian C. BRYAN, Steven DO, Joy DROBNICK, Alberto GOBBI, Tamiko KATSUMOTO, James Richard KIEFER, Jr., Jun LIANG, Naomi S. RAJAPAKSA, Yongsheng CHEN, Liqiang FU, Kwong Wah LAI, Zhiguo LIU, John WAI, Fei WANG
-
Publication number: 20200115383Abstract: Compounds of Formula 0, and stereoisomers and pharmaceutically acceptable salts thereof, as well as methods of use as Interleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.Type: ApplicationFiled: December 16, 2019Publication date: April 16, 2020Applicant: Genentech, Inc.Inventors: Marian C. BRYAN, Steven DO, Tamiko KATSUMOTO, Jun LIANG, Naomi S. RAJAPAKSA, James Richard KIEFER, Jr., Liqiang FU
-
Publication number: 20200115388Abstract: Compounds of Formula 0, and stereoisomers and pharmaceutically acceptable salts thereof, as well as methods of use as Interleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.Type: ApplicationFiled: December 16, 2019Publication date: April 16, 2020Applicant: Genentech, Inc.Inventors: Marian C. BRYAN, Joy DROBNICK, Alberto GOBBI, Tamiko KATSUMOTO, Naomi S. RAJAPAKSA, James Richard KIEFER, JR.
